Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes
By Giorgio Trinchieri P HAGOCYTIC CELLS and natural killer (NK) cells are among the effector cell types of innate resistance that represent a first line of defense against infections or foreign pathogens. During the early inflammatory response to an infection, regulatory interactions between these cell types take place, mostly mediated by cytokines that regulate activation and migration of phagocytic cells and NK cells. One of these mechanisms, often referred to as T-cell-independent macrophage activation, is observed in T-cell-deficient SCID mice.' When these animals are infected with Listeria monocytogenes or other bacteria, a rapid production of interferon-y (IFN-y) is observed that acts as a potent activator for phagocytic cells, increasing their bacteriocidal activity as well as their ability to produce cytokines. The major factor produced by the infected phagocytic cells and responsible for induction of production of IFN-y is interleukin-l2 (IL-12), a heterodimeric cytokine that is a potent inducer of cytokine production, particularly IFN-y, in T and NK cells, a growth factor for preactivated T and NK cells, and an enhancer of cytotoxic activity in both CD8' T cells and NK cell^."^ IL-12 is produced by phagocytic cells, B cells, and other antigen-presenting cell (APC) types.' In addition to its role in the phagocytic cell activation mechanism early in the inflammatory response to infections, APC-produced IL-12 has an obligatory role for the generation of T-helper type I (Thl) cells (producing IL-2 and IFN-y)*"" and for optimal differentiation of cytotoxic T lymphocytes (CTL)." The early decision towards Thl and Th2 cells in the immune response is dependent on the balance between IL-12, which favors Thl responses, and IL-4, which favors Th2 responses."'
IL-12, A CYTOKINE WITH A UNIQUE HETERODIMERIC STRUCTURE
NK cell stimulatory factor (NKSF) or IL-12 was identified as a factor secreted by human Epstein-Barr virus (EBV)-transformed B cell lines and mediating several biologic activities on human T and NK cells, including induction of IFN-y production, enhancement of cell-mediated cytotoxicity, and comitogenic effects on resting T cells.' NKSF/IL-12 was purified to homogeneity from the conditioned medium of the phorbol diester-stimulated RPMI-8866 EBVtransformed cell line and, unlike other cytokines, was shown to have a heterodimeric structure.' The genes encoding the two polypeptide chains of NKSF/IL-12 were cloned on the basis of partial amino acid sequences obtained from the purified proteins and biologically active recombinant NKSFAL-12 was produced in eukaryotic cells transfected with the cDNA for both NKSF/IL-12 chains: A cytotoxic lymphocyte maturation factor (CLMF) was also identified in the conditioned medium of an EBV-transformed B-cell line (NC37 line) on the basis of its ability to synergize with IL-2 in inducing the generation of lymphokine activated killer (LAK) cells.' Purification and cloning of the genes encoding CLMF showed that NKSF and CLMF are the same cytokine'.' and the unifying term of IL-12' is now widely accepted.
IL-12 is a heterodimer of 70 kD (p70) formed by two covalently linked glycosylated chains of approximately 40 kD (p40) and 35 kD (p35).* The p35 cDNA sequence encodes a 219 amino acid polypeptide"' corresponding to a mature protein with a calculated molecular weight (M,) of 27,500 containing 7 cysteine residues and 3 possible Nglycosylation sites. The p40 cDNA sequence encodes a 328 amino acid polypeptide with a 22 amino acid hydrophobic signal sequence, corresponding to a mature protein of calculated M, of 34,700 with 10 cysteine residues, 4 possible Nlinked glycosylation sites, and 1 consensus heparin binding site?.5 Transient transfection of COS cells or stable transfection of C H 0 cells with either p40 or p35 cDNA induces secretion of the respective IL-l2 chains, but cotransfection with both cDNA in the same cells is required for secretion of the biologically active form of 1L-12, the p70 heterodimer.J-5
The gene encoding the p40 chain has been mapped to human chromosome 5q31-q33, a region encoding several cytokine receptors and cytokines." The p40 gene is closely linked to the monocyte colony-stimulating factor (M-CSF) receptor and, interestingly, is in the same chromosomal region encoding 1L-4, the cytokine acting antagonistically to IL-l2 in determining the Thl/Th2 dichotomy. The gene encoding the p35 chain is a completely unrelated gene that has been mapped to human chromosome 3p12-3q13.2.'?
The two genes encoding the murine p40 and p35 chains were cloned by cross-hybridization with human cDNA clones and found to have 70% and 60% sequence homology, respectively, with the corresponding human genes." Human 1L-12 is not active on mouse cells, but murine IL-12 is active on both murine and human lymphocytes.' Interspecies heterodimers are active on both human and murine lymphocytes when the p35 chain is of murine origin, but are active only on human cells when the p35 chain is of human origin, regardless of the origin of the p40 chain, suggesting that the p35 chain has a determining effect on the species specificity of the heterodimer. ' The primary amino acid sequence of the IL-12 p35 chain indicates an a-helix-rich structure, similar to most cytokines. A comparison of the p35 amino acid sequence with For personal use only. on April 14, 2017. by guest www.bloodjournal.org From those of IL-6 and granulocyte colony-stimulating factor (G-CSF) showed that many of the amino acid positions that are conserved between these two cytokines are also conserved in IL-12 ~3 5 . '~ The p40 sequence is not homologous to any other known cytokine, but appears related to the hematopoietic cytokine receptor family, which is characterized by 4 cysteine residues and 1 tryptophan residue in conserved positions in the extracellular portion of these receptors and by a WSXWS motif.I4 The p40 sequence has a particularly significant sequence homology with the extracellular portions of two members of this family, the IL-6 receptor (IL-6R) and the ciliary neurotrophic factor (CNTF) receptor."I4 IL-6R, CNTF-R, and IL-12 p40 have an N-terminal Ig-like domain followed by the sequence characteristics of the receptor family; the WSXWS motif in the p40 sequence is modified by the insertion of an alanine (WSEWAS) and is near the C-terminus in the p40 molecule. Most cytokine receptors can also be released by cells in soluble forms that usually terminate immediately after the WSXWS motif and are produced either by proteolytic digestion of the transmembrane form or by alternative splicing of the message that eliminates the exons encoding the transmembrane and Cterminal cytoplasmic portion^.'^ The binding of IL-6 to the ILdR is a low-affinity interaction, but upon association with a dimer of gp130, which is a nonligand binding signal-transducing transmembrane component of several cytokine receptors, a high-affinity complex is produced and signal transduction through the gp130 chain is triggered.I6 The soluble form of the IL-6R, unlike most other soluble receptors, does not compete for binding of IL-6 to the cellular receptors; rather, the soluble IL-6R binds in solution with IL-6 and this complex can bind to gp130 on the cell surface, mediating signal transduction and IL-6 biologic
The CNTF-R is composed of three chains: gp130, shared with the IL-6R; the leukemia inhibitory factor (LIF) receptor 0 chain; and a CNTF-R a chain. Similar to the ILdR, the CNTF-Ra chain is released as a soluble form that binds to CNTF and the complex mediates signal transduction on cell types expressing gp130 and LIF-RP chain." It is therefore possible to hypothesize that heterodimeric IL-12 is evolutionarily derived from a primordial cytokine (p35 equivalent) that, similar to IL-6 or CNTF, had a multichain receptor. The transmembrane form of one chain of the receptor (p40 equivalent) was lost, but an efficient association of the primitive cytokine and the primitive soluble receptor was maintained through a covalent linkage between the two chains. This heterodimeric complex, similar to the soluble IL-6ML-6 or CNTF-Ra/ CNTF complexes, would still be able to bind with high affinity to the one or more remaining transmembrane chains of the receptor, inducing signal transduction and biologic activity. If this hypothesis on the evolutionary origin of IL-12 is correct, one would assume that, like IL-6 and IL-6R or CNTF and CNTF-Ra, the p35 and p40 chains of IL-12 have maintained a ligand receptor-like affinity for each other, even in the absence of the covalent linkage between the two chains. Indeed, when monomeric recombinant IL-12 p40 and p35 are added together to responsive cells, all the biologic activities of IL-12 can be shown (Rengaraju et al, unpublished results), although at concentrations from 2 to 5 orders of magnitude higher than those effective for the covalently linked heterodimer.
Analysis of steady-state binding data of IL-12 by Scatchard analysis identified a single binding site on PHA-activated lymphoblasts with an equilibrium dissociation constant of 100 to 600 pmol/L and 1, OOO to 9,000 sites/cell." Crosslinking and immunoprecipitation experiments with anti-IL-12 antibodies identified a single protein of approximately 110 D.'' The cellular distribution of IL-12R was analyzed by identifying cell-bound IL-12 with fluorescent anti-IL-12 antibodies. The presence of the receptor was detected on activated T or NK cells, but neither on B cells nor on resting T or NK cells.I9 The available data on IL-12R only explain in part the cellular specificity and biologic activities of IL-12. Some of the biologic activities, eg, the proliferative effect or the induction of IFN-y, can be shown at concentrations less than 1 pmol/L.2~20~21 If the dissociation constant of the identified receptor is more than 100 pmol/L, it is necessary to assume either that signal transduction takes place at minimal occupancy of the receptors or that additional unidentified chains of the receptor are required for determining a low number of high-affinity binding sites. The other discrepancy with the functional data is that receptors cannot be identified on resting T and NK cells, whereas certain biologic activities of IL-12, eg, enhancement of cell-mediated cytotoxicity or induction of IFN-y production, are mediated with a similar dose-response curve on both resting and activated NK and T c e k 2 ' It is not clear yet whether the p40 chain, the p35 chain, or both are directly involved in binding to the receptor. The observations that anti-p40 antibodies" and site-specific chemical modifications of a tryptophan residue on the p40 chainz3 block IL-12 binding to the receptor and that p35 is responsible for determining the species specificity of IL-1 26 suggest, however, that both chains may play a role.
Recent detailed analysis of IL-12 binding sites on phytohemagglutinin (PHA)-activated peripheral blood mononuclear cells (PBMC) has identified three binding sites with apparent affinities of 5 to 20 pmol/L, 50 to 200 pmol/L, and 2 to 6 n m~l / L .~~ These data suggest the existence of different forms or different chains in the IL-l2R, with the high-affinity form of the receptor possibly responsible for most of the biologic activities of IL-12. By screening of an expression cDNA library with an antibody able to precipitate the complex of IL-12R/12sI-IL-12 from cell lysates, a component of the human IL-12R was cloned.24 This subunit is a 662 amino acid type I transmembrane protein with an extracellular domain of 5 16 and a cytoplasmic domain of 91 amino acids.24 The subunit is a member of the hematopoietin receptor superfamily and most closely homologous, both in the extracellular and intracellular domain, to gp130, to the LIF-RP, and to the G-CSF-R.24 Cells transfected with this chain bind IL-12 with an affinity of 2 to 5 nmoVL, covalently linked dimers or oligomers are responsible for the binding, unlike gp130, which is dimerized only after IL-6 binding.24 A polyclonal antibody raised against this receptor inhibits IL-12-induced proliferation, suggesting that this chain is involved in mediating at least one of the functions of IL-12; however, the lowbinding affinity of this receptor chain suggests that other chains may be required for formation of high-affinity recept o r~. *~
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The signal transduction events after interaction of IL-12 with its receptor are largely unknown. Within a few minutes of exposure to IL-12, phosphorylation of several proteins is observed in the treated ~e l l s . '~.~~ Tyrosine kinase inhibitors suppress IL-12-mediated induction of CD69 expression and enhancement of cytotoxic activity in human NK cells.27 A different phosphorylation pattern is apparently observed in NK cells and T cells. ~5 6 ' '~ was reported to be primarily phosphorylated in resting and activated NK cells,25 whereas, in activated T cells, phosphorylation of mitogen-activated protein (MAP) kinase is observed." It has been suggested that these different signaling pathways may reflect the different activities of IL-12 on proliferation of T and NK cells. IL-12 increases IL-2-induced proliferation of activated T cells, but mostly inhibits IL-2-induced proliferation of NK ceIIs.20,2x
Production of IL-l2
The requirement for expression of two different genes to produce the biologically active IL-12 heterodimer renders the genetic control of the production of this cytokine particularly complex. Originally, IL-12 was discovered and purified from the conditioned medium of EBV-transformed human cell lines and phorbol diesters were found to increase severalfold the production of IL-12.*.' A screening of many different cell lines showed that the large majority of EBV-transformed B-cell lines produced IL-12 either constitutively or after phorbol diester tim mu la ti on.^ However, significant IL-12 production was not observed in cell lines of different origin, including Burkitt-lymphoma-derived lines, regardless of whether they expressed EBV.7 All the cell lines producing the biologically active p70 heterodimer also produced a large excess, usually from 10:l to 50: 1, of the free p40 heavy hai in.^,^ The production of the p40 chain, either free or associated in the heterodimer, can be easily measured both in the human and in the mouse system by a two-determinant capture radioimmun~assay.~ The production of the biologically active p70 heterodimer is more difficult to evaluate and relies on two different methods: (1) a radioimmunoassay using the 20C2 monoclonal antibody (MoAb)?' which is relatively specific for the p70 dimer, but which also crossreacts with the p40 chain, necessitating a correction factor that affects the reliability of the assay7; and (2) an antibody capture biologic assay, based on the capture of IL-12 on plates coated with a nonneutralizing anti-p40 MoAb, followed by the addition of indicator cells (NK cells or PHA blasts in humans, spleen cells in mice) and evaluation of either IL-12-induced pr~liferation~~ or IFN-7 production.'" The physiologic significance of the production of the free p40 chain is not clear. It was reported that in the mouse recombinant free p40 inhibits the biologic activity of the p70 heterodimer, suggesting that p40 may act as a physiologic antagonist of IL-12.3' However, we have observed that the inhibitory activity of recombinant murine p40 resides primarily in p40 homodimers formed by recombinant protein and it is not clear yet whether natural p40 also has antagonistic activity; furthermore, little if any antagonistic activity was demonstrable in human recombinant p40 (Wolf et al, unpublished observation and Gately, personal communication). The secretion of p40 homodimers, which may compete for IL-12 binding to its receptors, were, however, also described in cells transfected with human p40 cDNA.?' When expression of mRNA for the p40 and p35 chains was analyzed in cell lines, the expression of p40 transcripts correlated with the ability of the cell lines to produce IL-12, whereas the p35 transcripts were ubiquitously expressed in almost all cell lines, of various hematopoietic and nonhematopoietic origin.'," Although sensitive radioimmunoassays able to detect the p35 chains are available, secretion of p35 free chain from either cell lines or normal cells has never been demonstrated, an indication possibly of the difficulty of secretion of p35 if not in association with p40, as suggested also by a poor production of p35 in cell lines transfected with the p35 cDNA.' It is difficult at the present time to understand the apparently poor regulation of the expression of the two IL-12 genes, with overexpression of the p40 genes in the producer cells and expression of p35 transcripts in cells not expressing the p40 genes. It is possible that the individual p40 and/or the p35 chains have yet undemonstrated functions, different from those of the p70 heterodimer; alternatively, either chain may associate with unrelated polypeptides to form heterodimers with different functions. It is also possible that the apparently inefficient regulation of the expression of the two genes reflects the evolutionary origin of IL-12 genes from genes encoding a putative primordial receptor and a cytokine, which might have been in part expressed in different cell types and the expression of which did not need to be quantitatively correlated.
When the production of IL-12 from normal PBMC was analyzed, the major producer cells of IL-12 were found to be monocytes or monocyte-derived macrophages, although B cells and other major histocompatibility complex (MHC) class 11-positive cell types were also found to be producers.' Surprisingly, phorbol diesters did not enhance production of IL-12 by peripheral blood cells, unlike what is observed in EBV-transformed B-cell lines, but the most efficient inducers of IL-12 production were found to be bacteria, bacterial products, and intracellular parasites.' Gram-positive and -negative bacteria, endotoxins, mycobacteria, and intracellular parasites such as Toxoplasma gondii were all efficient inducers of IL-12 p r o d~c t i o n .~.~~ Because of the ability of endotoxin to induce IL-12 production, a high background production of IL-12 is observed when precaution is not taken to purify and culture PBMC in strictly endotoxin-free condit i o n~.~ In addition to PBMC, peripheral blood neutrophils were also shown to be able to produce IL-12 in response to lipopolysaccharide (LPS).'s As observed in cell lines, stimulated PBMC and neutrophils produced the free p40 chain in a 10-to 50-fold excess over the biologically active p70 h e t e r~d i m e r .~.~~ Both p40 and p35 mRNA were constitutively expressed at very low levels in unstimulated peripheral blood cells and accumulation of both was upregulated by stimulation with bacteria or bacterial products, although the induction of the p40 gene was much more marked, resulting in abundance of p40 transcriptions in stimulated cells up to 200-fold higher than that of p35 transcripts, explaining the excess production of the Besides LPS, the bacterial molecules responsible for induction of IL-12 or other monocyte-derived cytokines are poorly characterized. Because of the possibilities that production of IL-12 may be differentially regulated compared with that of other monokines such as IL-1, TNF-a, and IL-1036.37 and because of the importance of cytokine-inducing molecules in the vaccine adjuvant effect of bacterial preparations, this field of research is receiving increasing attention. Various types of phagocytic cells respond to various inducer stimuli with different efficiency. For example, heat fixed Staphylococcus aureus is a much stronger inducer of IL-12 production in PBMC than LPS, whereas LPS is a stronger stimulus for neutrophils and myeloid cell
The initial analysis of human cell lines for constitutive or phorbol diester-induced IL-12 production identified only Bcell lines as producers.' However, by inducing the cell lines with LPS, several human myeloid leukemia-derived cell lines, including THP-1, ML-3, and HL-60 (but not U937 or other cell lines) were shown to be able to produce lL-12. 36 In certain experimental conditions, treatment with inducers of differentiation (eg, short treatment with dimethyl sulfoxide) enhanced the ability of the cell lines to produce IL-12. 36 Similar to the human cells, both B and macrophagic murine cell lines have been shown to produce IL-12.38.39 Both in vitro and in vivo bacteria and LPS induced production of IL-12 in m i~e~~'~; because LPS induced similar IL-12 levels in normal and B-cell-deficient SCID mice, it is likely that macrophages rather than B cells are the major physiologic IL-12 producers. 40 The ability of phagocytic cells to produce IL-12 is regulated by several cytokines with activating or deactivating effects on the producer cells. IFN-y and GM-CSF are among the cytokines that enhance the production of IL-12 from phagocytic cells.36 IFN-y treatment of monocytes or neutrophils does not directly induce accumulation of p40 mRNA, but enhances the accumulation in response to other stimuli, eg, LPS; unlike p40, both constitutive and stimulated accumulation of p35 mRNA is enhanced by IFN-y treatment.39 Probably because of this direct effect of IFN-y on p35 mRNA accumulation, the ratio of p70:free p40 is higher in cells stimulated in the presence of IFW-Y.~~ The cytokines with an inhibitory effect on IL-12 production include IL-10, IL-4, and TGF-p.30.40" These cytokines inhibit both IL-12 protein secretion as well as p40 and p35 mRNA accumulation in stimulated phagocytic cells. The ability of IL-10 to inhibit IL-12 production by accessory cells is the major mechanism by which IL-10 inhibits IFN-y production by IL-12 also enhances the colony formation by highly purified human progenitor cells, either multilineage or lineagecommitted, stimulated by SF and IL-3."' All these stimulatory effects of IL-12 on hematopoiesis appear to be direct on the progenitor cells and are not mediated through other cytokines induced by IL-12. Thus, IL-12 appears to belong to the group of synergistic early acting hematopoietic cytokines, including IL-6, G-CSF, and IL-11, and distinct from cytokines such as SF, IL-3, or IL-4." However, if IL-12 is added to human progenitor cells together with a small number of NK cells, it inhibits colony formation by inducing NK cells to produce the inhibitory cytokines IFN-y and tumor necrosis factor-a (TNF-CY).~~ Because IL-12 has a direct stimulatory effect on hematopoietic stem cells and an indirect inhibitory effect by inducing production of inhibitory cytokines by NK cells and, possibly, by T cells?9 it is difficult to predict the possible physiologic role of IL-12 in in vivo hematopoiesis. Treatment of mice with daily intraperitoneal (IP) doses of 1 pg IL-12 has been shown to have profound effects on hematopoietic homeostasis, with neutropenia, anemia, and appearance of extramedullary hematopoietic foci in the spleen and For personal use only. on April 14, 2017. by guest www.bloodjournal.org From liver." The liver histology in IL-12-treated mice is characterized, in addition to the presence of hematopoietic foci, by focal hepatocyte necrosis and elevation of hepatic transaminases, with an increased number of macrophages, NK, and CD8' T cells, but not of CD4+ T cells." The extramedullary hematopoiesis is mostly responsible for the splenomegaly observed in the IL-12-treated mice." It is therefore apparent that IL-12 treatment in vivo has a profound effect on hematopoietic cells, but it is difficult to identify the role of direct effects of IL-12 on progenitor cells, that of IL-12-induced cytokines (eg, IFN-y and TNF-a), or that of other effects on the hematopoietic cells (eg, cell mobility and migration) or on other cell types (eg, endothelial cells). IL-12 induces a similar hepatotoxicity but a much more severe anemia than observed in IL-2-treated mice; unlike IL-2-treated mice, IL-12-treated mice did not develop mononuclear cell infiltrates and pulmonary edema.sl~"
In addition to its effect on early hematopoietic cells and lineage-committed myeloid progenitor cells, IL-12 has been shown to influence intrathymic T-cell d e~e l o p m e n t .~~
In fetal organ cultures, IL-12 determined a decrease in most thymocyte subsets, but an increase, both proportional and absolute, of the number of aPTCR+ CD4-CD8+ thymocytes.53 When added to isolated thymocyte subsets, IL-12, in combination with IL-2 and IL-4, caused proliferation of CD3' CD4-CD8' cells and, in combination with SF, of early triple negative (CD3-CD4-CD8-), CD44+ CD25+ pro-T cells? Because stromal cells from both fetal and adult mouse thymuses express p35 and p40 mRNA and are a potential source of IL-12,5' the physiologic role of IL-12 in regulating intrathymic T-cell development deserves to be investigated.
Induction of Lymphokine Production by IL-12
One of the most potent and probably physiologically relevant functions of IL-12 is its ability to induce both NK and T cells to produce lymphokines, particularly IFN-Y.~ Like IL-2 and a few other cytokines, IL-12 induces NK and T cells to accumulate mRNAs and to secrete IFN-y, TNF-a, GM-CSF, M-CSF, IL-3, IL-8, and IL-2.2,4.2",21.34.54-sy Whereas the ability of IL-12 to induce most of these cytokines is lower or at most comparable with that of IL-2, IL-I 2 is selectively powerful in inducing IFN-y production as a single stimulus and as a synergistic inducer together with other IFN-y inducers. On T cells, IL-12 synergizes in inducing IFN-y production with IL-2, phorbol diesters, mitogenic lectins, and T-cell receptor (TCR)/CD3 stimuli such as anti-CD3 antibodies, alloantigens, and specific antigens2".*'; on NK cells with IL-2, phorbol diesters, Fc receptor ligands (immunocomplexes, IgG-coated cells, anti-CD1 6 antibodies), and NK susceptible target cells.20~21 Both resting and activated NK and T cells are induced by IL-12 to produce IFN-y, although maximal IFN-y mRNA accumulation is reached in 2 to 4 hours in activated T or NK cells and in 18 to 24 hours in resting peripheral blood lymphocytes (PBL)." Within PBL, IL-12 induces mRNA accumulation, as detected by in situ hybridization, in a proportion of both NK and T cells:' although NK cells might be a major contributor to the early production of IFN-y in response to IL-12 or IL-2.60 As discussed above, the ability of IL-12 at concentrations as low as I to 5 pmoVL to induce IFN-y on resting T and NK cells is difficult to reconcile with the fact that IL-12 receptor cannot be detected on resting PBL." However, it is possible that a small number of high-affinity receptors, undetectable by the presently available methods, are expressed on a proportion of PBL and responsible for the IL-12 effect. It should also be noted that in peripheral blood CD56' NK cells, IL-12 has been shown to upregulate its own receptor," which is perhaps a mechanism of regulation explaining the ability of IL-I 2 to induce resting PBL. Although NK and T cells are the IFN-y producers in PBL preparations stimulated by IL-12, an accessory cell type (MHC class 11-positive, non-monocyte, non-B cells) is required for optimal IFN-y production by resting PBL." Although the nature of these accessory cells has not yet been identified, they might provide costimulatory molecules for IFN-y production. In murine spleen cells, it has been shown that IL-12 synergizes with TNF-a in inducing IFN-y producti~n.'~.'* This synergistic effect of TNF-a was not shown with human lymphocytes, but antibodies to TNF-a or IL- and blocking of B7-CD28 interaction with the hybrid recombinant molecule CTLA4-Ig significantly inhibited the ability of PBL to produce IFN-y in response to IL-12.'' These results suggest that TNF-a, IL-lp, and B7, possibly at least in part provided by the class 11-positive accessory cells, are important costimulators for IFN-y production in response to IL-12. The ability of IL-10 to inhibit IFN-y production in T and NK cells is primarily due to its ability to suppress IL-12 production, but also, in part, because of its ability to suppress expression of these costimulatory molecules on accessory ~e l l s .~~~~'~~~ The mechanisms by which IL-12 induces IFN-y production and synergizes with IL-2 in this effect have been investigated.54.56 Whereas IL-12 directly induced an increase in the transcriptional rate of the IFN-y genes, the combination of IL-12 with IL-2 did not induce an additional increase in transcription, but increased the half-life of the IFN-y mRNA ~everalfold.'~ Thus, both transcriptional and posttranscriptional mechanisms are involved in the regulation of IFN-y gene expression by IL-12. IL-12 and IL-2 did not show the same strong synergistic effect in induction of other cytokines, either at the protein or the mRNA 1eve1,20~56 although additive or, in some cases, more than additive effects were observed when IL-12 was used in combination with IL-2 or other stimuli." For example, relatively high concentrations of TNF-a or GM-CSF were produced by T cells stimulated by IL-12 and anti-CD28 antibodiess7
Not only is IL-12 a potent inducer of IFN-y production, but it is also most likely a required factor for efficient WNy production depending in vivo and in vitro on accessory For personal use only. on April 14, 2017. by guest www.bloodjournal.org From cells. When human PBMC were treated in vitro with stimuli, eg, S aureus, that were able to induce production of IL-12, they rapidly produced large amounts of IFN-y. This production of IFN-y was almost completely inhibited by neutralizing antibodies against IL-lT7 Even when IFN-y inducers that are not known to stimulate L-12 production were used (eg, IL-2 or anti-CD3 antibodies), the production of IFN-y from PBMC was inhibited up to 80%, indicating that endogenously produced IL-12 is required for optimal IFN-y prod~ction.~ However, if purified T or NK cells, in the absence of IL-12-producing accessory cells, were stimulated to produce IFN-y (eg, by IL-2 or anti-CD3 antibodies), no inhibitory effect of anti-IL-12 antibodies could be shown. ' Injection of mice with a daily IP injection of l pg of recombinant IL-12 induced high levels of serum IFN-y, but only starting 48 hours after the first injection." This delayed response was probably caused by the lack of appropriate costimulatory signals when only recombinant IL-12 was injected. The injected IL-12 had a serum half-life of 3.3 hours:' much longer than that of other cytokines. The ability of IL-12 to induce a rapid production of IFN-y in vivo has been clearly shown in several experimental models of infectious diseases discussed below. A very informative experimental model for the understanding of the role of IL-12 in inducing IFN-y in vivo is provided by the endotoxic shock in Bacille Calmette GuCrin (BCG)-primed mice.40 Several cytokines, particularly TNF-a and IFN-y, have been shown to be responsible for pathologic reactions that may lead to shock and death observed in infection with gram-negative bacteria and in response to endotoxins. Priming of mice with the avirulent BCG vaccine strain of Mycobacterium bovis increases the sensitivity of mice to the lethal effect of LPS and results in an efficient priming for cytokine production in response to LPS. Mice injected with LPS produced IL-12 that controlled IFN-y production, as shown by the ability of neutralizing anti-IL-12 antibodies to suppress IFN-y production.40 However, the concentration of biologically active E-12 p70 heterodimer was similar in the serum of both BCG-primed or unprimed mice, reaching levels of 1 to 3 ng/mL at 3 to 6 hours after LPS injection, whereas IFN-y production was observed only in BCG-primed mice.40 TNFa and other LPS-induced cofactors were required in cooperation with IL-12 to induce optimal IFN-y production. The priming effect of BCG on IFN-y production appears to be mostly caused by its ability to increase TNF-a production, which acts as cofactor with LPS-induced IL-12 in inducing IFN-y production.40 Neutralizing anti-IL-12 antibodies, in addition to inhibiting the in vivo LPS-induced IFN-y production, also protected mice from septic shock-induced death!' Thus, IL-12 is required for IFN-y production and lethality in an endotoxic shock model in mice.
In addition to the endotoxic shock model, the important role of IL-12-induced IFN-y production was demonstrated in the generalized Shwartzman reaction in mice.63 In this model, mice are sensitized to an intravenous (IV) injection of LPS with a local injection, 24 hours earlier, of a low LPS dose in the footpad. The importance of the LPS-induced IL-12 and of IL-12-induced IFN-y in the sensitization phase was demonstrated by the observations that (l) the sensitization was blocked by neutralizing antibodies to either IL-12 or IFN-y and that (2) LPS sensitization could be replaced by injection of either IL-12 or I F N -Y .~~
Enhancement of NK and T-Cell-Mediated Cytotoxicity by IL-12
The ability of IL-12 to enhance lymphocyte-mediated cytotoxicity was one of the first IL-12 activities to be described and responsible for the original designation of IL-12 as NK cell stimulatory facto3 and cytotoxic lymphocyte maturation f a~t o r .~ Incubation of PBL or purified NK cells with L 1 2 for incubation times of 8 hours or longer enhanced severalfold NK cell cytotoxic activity against both NK cell-sensitive and -resistant target
The ability of NK cells to lyse virus-infected target cells, including human immunodeficiency virus (H1V)-infected cells& and, to a lesser extent, antibody-coated target cells (antibody-dependent cell-mediated cytotoxicity [ADCC])''.@ was also enhanced by IL-12. The enhancement of NK cell-mediated cytotoxicity was paralleled by increased binding to the target cells and by an increase in granularity of NK ~ells,6'.~~ probably reflecting an effect of IL-12 on the expression of adhesion molecules and granule-associated proteins, as discussed below. IL-12-treatment also had positive modulatory effects on NK cell granule exocytosis induced by CD16IFcyFUII triggering, activation of protein kinase C, or stimulation of G proteins.67 The effect of IL-12 on cytotoxicity appears to be direct on NK cells, because it was observed with highly purified preparations of NK c e 1 1~' '~~~~~~ and, unlike the IFNy production by PBL?' does not require the participation of accessory cells.''~@ The activation of NK cells by IL-12 was not dependent on the production by NK cells of cytokines with NK cell enhancing activity such as IL-2, IFN-a, or IFN-y.2,"*68 Unlike IL-2-mediated enhancement of NK cellmediated cytotoxicity, the effect of L 1 2 was not inhibited by IL-4.27,2s Antibodies against TNF-a have been shown to inhibit the enhancing effect of IL-12 on NK cell cytotoxicity in one study:' but not in another one,@ suggesting that endogenously produced TNF-u may cooperate with IL-12 on some NK cell subsets or experimental conditions, but not in others.
Even when optimal concentrations of IL-12 are used, the enhancement of NK cytotoxicity induced by TL-12 is usually lower than the optimal enhancement obtained with IL-2 or with IFN-(Y.~ However, enhancement of NK cell-mediated cytotoxicity was observed with concentrations of IL-12 of less than 1 pmoVL, whereas concentrations of E -2 or IFNa up to 3 orders of magnitude higher were required for similar effects.' Unlike the induction of IFN-y production from PBL or NK cells, stimulation of NK cells with combination of IL-12 and IL-2 resulted in an additive, but not a synergistic, effect on cytotoxic activity.@
In vivo treatment of mice with daily IP injection of IL-12 determined a striking increase of NK activity in spleen and liver with a maximum after the second injection and declining thereafter.5' This decrease in NK cells activity during continuous cytokine treatment was previously observed with IFN-a treatmenf9 and it is not caused by a decreased For personal use only. on April 14, 2017. by guest www.bloodjournal.org From number of NK cells, because they increase rather than decrease with continuous IL-12 treatment.?' It is possible that inhibitory mechanisms, possibly dependent on IFN-y-mediated macrophage activation, were responsible for the observed decline in NK activity, as previously observed during IFN-a treatment."
In addition to short-term activation of NK cells, IL-12 also induces generation of LAK cells in culture of PBL' or purified NK cells.?' The IL-12 effect of IL-12 on the generation of LAK cells was not blocked by antibodies to IL-2 or IFN-7, but was significantly inhibited by antibodies to TNFa , I I .ss Because 1L-l2 induces only minor levels of TNF-a from purified NK cells and TNF-a alone is not an inducer of LAK cell generation, it is likely that endogenously produced TNF-(Y acts as a cofactor together with IL-12 in the generation of LAK cells.'5 The requirement for production of TNFa and, possibly, of other costimulatory molecules probably explains the observation that, in the presence of hydrocortisone, which inhibits endogenous cytokine production, IL-12 alone was unable to induce generation of LAK cells, but synergized with IL-2 in this effect.',' It is noteworthy that anti-IL-12 antibodies decreased the generation of LAK cells induced by IL-2, suggesting a role for endogenously produced IL-12 in this phenomenon."
In addition to its effect on NK cell cytotoxicity, IL-12 also enhances T-cell-mediated cytotoxicity and has an enhancing effect on the generation of CTL. IL-12, similar to, although not as powerfully as IL-2, induced in peripheral blood T cells the ability to lyse anti-CD3 antibody-coated Fc-receptorpositive target cells (reverse ADCC)." The spontaneous cytotoxicity mediated by acute T-cell leukemia (T-ALL)-derived cell lines was enhanced by short-term treatment with IL-12.'j5 IL-12 enhanced IO-to 20-fold the generation of cytotoxic cells lytic for anti-CD3 hybridoma target cells from human CD8' cells stimulated by immobilized anti-CD3 antibodies7" This effect of IL-12 was not dependent on secretion of IFN-y or IL-L7" The in vitro generation of both human and murine allospecific CTL was enhanced by IL-12.'i,7' The mechanism of CTL enhancement was shown to be IL-2 dependent in human T cells," but not in murine T cells.7' The increase in mouse allospecific CTL activity was equivalent either when IL-I 2 was added at the beginning or during the last day of the 5-day mixed leukocyte cultures used for CTL generation, suggesting that IL-l2 enhances both the generation and the cytotoxic activity of CTL."
The rapid enhancement of NK cell cytotoxicity by IL-12, observed within a few hours of treatment, and the modest effect of IL-12 on cell proliferation, particularly of resting NK cells, suggest that proliferation plays a minor role in the IL-12-mediated enhancement of cytotoxicity. The increased ability of IL-12-treated NK cells to form conjugates with target ~e l l s ' j~~~~ is probably caused by an upregulation of NK cell adhesion molecules. induces an upregulation on NK cells of the following activation markers and cell-adhesion molecules: CD2, CD54, CD56, CD69, and CD71 .28.5s.72
Within the p2 integrins, 1L-12, similar to IL-2, upregulates CD1 1 a but not CD 1 1 b e x p r e s s i~n~* .~~; unlike IL-2, IL-12 did not upregulate any of the PI integrins on NK cells." Although IL-2-activated NK cells have increased integrin-dependent adhesion to fibronectin-or laminin-coated surfaces, 1L-12-activated NK cells were unchanged in their adhesion to laminin and were less adherent than IL-2-activated cells to fibronectin7*; although overall the effect of IL-12 on adhesion functions of NK cells was more moderate than that of IL-2, IL-12 was active at much smaller doses than IL-2,72 suggesting a possible physiologic relevance of these effects. The changes in adhesion properties of IL-12-treated NK cells together with an enhanced migratory activity" and with a chemotactic effect of IL-12 on NK cells7' are likely to play a role in vivo in the NK response to endogenous or administered IL-12. In addition to the upregulation of adhesion-related molecules, IL-12 induced or enhanced expression of cytokine receptors on NK cells, in particular the a (p%) and , B (p75) chains of the IL-2 receptoix.55 and the p75 TNF Anti-IFN-y antibodies inhibited the enhancement of the p75 TNF-R in IL-12-treated NK cells, but induced expression of the p55 TNF-R, suggesting that the effect of IL-12 on the p75 TNF-R is mediated by IFNy and that IFN-y has opposite effects on the expression of the two TNF-R.hX The ability of IL-l2 to modulate the expression of cytokine receptors on lymphocytes has probably a role in affecting the responsiveness of the lymphocytes to the cytokine cascade during inflammation or immune response. IL-12 treatment also resulted in an increase in the number of cytoplasmic granules in NK cells,hh concomitant with an increased expression of proteins and mRNA for the granule-associated serine esterases, granzyme A and granzyme B, and for the pore-forming protein perforin, dependent, at least in part, on transcriptional a c t i v a t i~n .~~~"~~"~~ The ability of IL-12 to increase the expression of these cytotoxicity-related proteins, which was observed in NK ce11s,'6~6s~74 CD8' cells,7') and T-ALL cells:? as well as to modulate the stimulus-dependent granule exo~ytosis'j~ is likely to play a key role in the mechanisms by which IL-12 treatment enhances the cytotoxic potential of NK cells and CTL. 
Effect
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proliferation was observed at 2 to 4 days after PHA stimulation and then declined rapidly after day 6, similar to the expression of detectable IL-l2R.I9 IL-12 also synergizes with low doses of IL-2 in inducing proliferation of PBMC from day 7 to 1 l of culture, whereas at earlier times of culture no cooperation between L 1 2 and IL-2 was observed79; these kinetics also correlate with the ability of IL-2 to induce IL-12R expression on PBL from day 4 to 10 of culture." Thus, it appears that for IL-12 to induce T-cell proliferation, IL-12R needs to be induced above the level present on resting peripheral blood T cells. The ability of PHA blasts to proliferate in response to IL-12 and the enhancing effect of IL-12 on the proliferation of PBL induced by PHA on day 4 to 6 of culture and induced by IL-2 on day 7 to 11 is compatible with this hypothesis. Whether the ability of IL-12 to enhance the proliferation of PBL induced by phorbol diesters already at day 3 of culture' is caused by the ability of these compounds to rapidly induce IL-12R expression remains to be investigated. However, the available data on expression of IL-12R and responsiveness to IL-12 are difficult to interpret. The half-maximal proliferative response to IL-12 was observed at concentrations of the cytokine between 1 and 10 p r n~I / L ,~'~~~ much lower than the observed Kd of IL-12 binding to PHA furthermore, resting T and NK cells, which do not proliferate in response to IL-12, are rapidly induced to produce IFN-y by picomolar concentrations of IL-12. ' Human CTL lines, which proliferated in response to IL-12 alone, proliferated in response to IL-12 only when activated by anti-CD3 antibodies"; the proliferative response to IL-12 was independent of endogenously produced IL-2." Human (Kubin et al, unpublished results) and murine" Thl clones also proliferated in response to IL-12 only when COstimulated by antigen, anti-CD3 antibodies, or mitogens; unlike the human CTL lines, the IL-12-induced proliferation of murine Thl clones was dependent on IL-2 production in the c~ltures.~' Murine Thl clones anergized in vitro by treatment with soluble anti-CD3 antibodies as well as anergized CD4+ T cells isolated from mice tolerized to the Mls-1" antigen in vivo showed defective induction of proliferation to IL-12 upon restimulation with antigens, indicating that Tcell clonal anergy results not only in failure to produce the autocrine growth factor IL-2, but also in lack of responsiveness to the APC-derived cytokine IL-12."
The proliferation induced by IL-12 is largely IL-2 independent and anti-IL-2 or anti-IL-2R antibodies minimally inhibit proliferation in most experimental system^.'^.^^ However, the maximal proliferation induced by IL-12 in preactivated T or NK cells was usually only between 10% and 50% of the maximal proliferations induced by IL-2.3.20,79 When IL-12 and IL-2 were added together to PHA blasts, an additive effect was observed on proliferation, unlike the strong synergistic effect of these two cytokines on IFN-y producti~n.''.~~ However, on NK cells and on T cells with ybTCR, IL-12 inhibited IL-2-induced proliferation to the level of proliferation induced by IL-12 alone, especially when high doses of IL-2 (2 100 U/mL) were
The antagonistic effect of IL-12 on IL-2-induced proliferation of NK cells depended on the activation state of the cells: highly activated NK cells, expressing high levels of CD25 (L-2Ra) and other activation markers, were not inhibited by IL-12, whereas NK cells collected from later times of culture, past the peak of proliferation or expression of activation antigens, were sensitive to the inhibitory effect of IL-12.20 IL-12 was also inhibitory for the IL-2-induced proliferation of purified fresh NK cells?' although L-12 present during coculture of PBL with EBV-transformed B-cell lines had a strong enhancing effect on the endogenous IL-2-dependent expansion of NK cells in these cultures. 78 The effect of IL-12 on the proliferation of ybTCR+ T cells was confirmed by its ability to suppress the IL-2-dependent proliferation of a ysTCR+ T-ALL-derived cell line." Although IL-12 was shown to enhance IL-2-dependent proliferation of both CD4+ and CD8+ T cells contained in PHA blast prepara- and that IL-12 treatment upregulated the expression of IL-4R, suggesting that a reciprocal regulation of each other cytokine receptor may play a role in this synergy.6' Although IL-12 was able to induce proliferation of activated T and NK cells at very low concentrations, the reduced levels of proliferation compared with those induced by IL-12 raise concern over the physiologic relevance of IL-12 as a proliferative stimulus in vivo for T and NK cells. It was therefore particularly interesting the finding that the costimulation of either PHA blasts or even PBL with antibodies against the T-cell surface receptor CD28 or with one of the CD28-ligand, B7.1, transfected on L cells, strongly synergized with L 1 2 in inducing lymphocyte pr~liferation.'~ In the presence of B7/CD28 costimulation, L-12 induced proliferation of T cells higher than that obtained with maximal IL-2 stimulation, and it was effective at concentrations 100-to 1,000-fold lower than effectual concentrations of IL-2; the proliferative effect of anti-CD28 and IL-12 was resistant to moderate doses of cyclosporin A and was largely independent of endogenous IL-2.57 Equivalent results with murine Th 1 CD4' clones indicate that the proliferation of the clones in response to antigen and spleen APC was dependent on B7 (expressed on APC or on B7-transfected third party L cells) and IL-12 (either produced by the APC or exogenously added).41 Interestingly, the induction of IL-12 responsiveness in murine Thl clones by antigen and APC was inhibited by cyclosporin A, but the IL-12-induced proliferation of clones preactivated by antigen and APC was cyclosporin A insensi-
tive.** These results suggest that TCR stimulation by antigen induces IL-12 responsiveness, possibly dependent on induced IL-12R by a mechanism that may require IL-2-and/ or other cyclosporin A-sensitive signals, whereas the IL-12-induced proliferation of the responsive cells is cyclosporin A-resistant and IL-2-independent. These in vitro results suggest that the synergy between B7 and IL-12, a surface antigen and a soluble product, respectively, of APC may have a central role in regulating T-cell activation and immune response in the microenvironment of inflamed tissues.
Role of 1L-12 in the Development of Thl Cells
The powerful effect of IL-12 in rapidly inducing IFN-y production both in vitro and in vivo raised the question whether this cytokine was also involved in the differentiation or selection of the major T-cell type responsible for IFN-y production during an immune response, the Thl cells." Several recent studies both in h~r n a n s "~'~'~~~~ and in the ing and probably required for Thl cell development, acting in an antagonistic equilibrium with IL-4, which favors differentiation of the Th2 cells." These in vitro observations have been fully confirmed by in vivo experimental models of infection or immunization, reviewed below.
Stimulation in vitro of PBL from atopic patients with allergens such as Dermatophagoides pteronyssinus group 1 (Der p. I ) resulted in the generation of T-cell lines and clones with high IL-4 and low IFN-y production typical of Th2 cells, whereas PBL stimulation with bacterial products (eg, purified protein derivative [PPD]) generated Thl-type T-cell lines and clones that produced IFN-y but not IL-4. When PBL were stimulated with Der p.1 in the presence of IL-12, T-cell lines were generated that exhibited a reduced ability to produce IL-4 and an increased ability to produce IFN-Y.~ These cell lines developed into Der p.1-specific CD4' T-cell clones exhibiting a Tho-(producing both IFN-y and IL-4) or Thl-phenotype (producing only IFN-y). This Thlinducing effect of IL-12 was not inhibited by anti-IFN-y, but was reduced by removal of NK cells from the PBL preparations. Thus, the effect of IL-12 is at least in part independent of IFN-y production, but might require the participation of NK cells. PPD-specific T-cell lines generated in the presence of anti-IL-12 antibodies during the initial antigenic stimulation produced significant levels of IL-4, unlike the cell lines generated in the absence of antibodies, and gave rise to PPD-specific CD4' cell clones showing a Tho/ Th2 phenotype rather than a Thl phenotype.x These results indicate not only that IL-12 is able to facilitate proliferation and activation of Th 1 cells in a memory response in vitro, but also that, as shown by the effect of anti-IL-l2 antibodies, endogenously produced IL-12 is an obligatory factor for Thl generation in vitro in response to bacterial antigens.
The results obtained with the analysis of human T-cell response to recall antigens clearly showed that memory T cells with a predominant ThO/Thl phenotype in the case of bacterial antigens and a ThO/Th2 phenotype in the case of allergens can be modulated in vitro to generate either Thl or Th2 clones depending on the cytokine pattern present during the in vitro restimulation. Whether this ability to shift m0use9,86. 87 have indeed identified IL-12 as a factor facilitatcytokine production phenotype during in vitro stimulation reflected a plasticity of still incompletely differentiated Th cells or rather the selective expansion of few clones of phenotypes different from the predominant ones remained undetermined.
To determine whether IL-12 has an effect on the maturation of naive human CD4' T cells, neonatal (cord blood) CD4' T cells were Culture for 1 week in the presence of IL-l2 rendered cord blood CD4' cells able to produce IFN-y, whereas freshly purified CD4' cord blood cells were unable to produce IFN-y even in response to phorbol diesters and Ca2+ ionophore." This IL-I 2-mediated priming of naive cord blood CD4+ cells for IFN-y production was enhanced severalfold when irradiated cord blood mononuclear cells, IL-2, TNF-a, or IL-1 were added to the c~ltures.'~ Interestingly, if cord blood CD4' cells were expanded for 3 weeks in IL-4, they produced Thl cytokines (IFN-y and IL-2) but not Th2 cytokines (IL-4 and IL-S)." If IL-I 2 and IL-4 were presented during the priming, cell cultures that produced very high levels of both IFN-y and IL-4 were obtained, indicating that IL-12 in this experimental system may allow the IL-4-mediated priming for IL-4 production to develop in the culture, while concomitantly inducing priming for IFN-y production.xs
The experimental systems used to date have not permitted determination of whether the different cytokines affecting Th cell development, IL-12 in particular, induce differentiation of bipotential Th precursors or rather a selective priming andor expansion of already committed Thl and Th2 precursor cells.5y~x'~y" This question is particularly relevant in the case of human studies that have analyzed clonal expansion of memory Th However, once a Thl or Th2 response has been established, it appears to be relatively stable, and no factors capable of inducing qualitative changes in the cytokine profile of established murine or human T-cell clones have been reported.
In the experiments of analysis of cytokine production from human T cells stimulated with recall antigens (PPD) or allergens (Der Pl), the expansion of a small proportion of memory T cells was first obtained in polyclonal T-cell cultures, from which single antigen-specific clones were obtained only after several weeks of culture of the polyclonal cell line.'," During this culture period, emergence of Th cell subsets, with characteristic cytokine production profiles, could be caused by differentiation of precursor Th cells, as well as by positive selection (growth advantage) of certain Th subsets or negative selection (cytotoxicity, antiproliferative effect) of other subsets. When the Th response in vitro to PPD and Der p1 was analyzed, the presence of endogenous or added recombinant IL-12, respectively, during antigenic stimulation was observed to induce a striking decrease in IL-4 production and a more modest enhancement of the ability of the T cells to produce IFN-7.' The results were equivalent when the polyclonal T-cell culture or the antigenspecific CD4' T-cell clones derived from them were anal y~e d .~
To analyze whether the effect of IL-12 on the cytokine profile of T cells was due to differentiation of single cells or selective mechanisms, clonal growth of virtually every T For personal use only. on April 14, 2017. by guest www.bloodjournal.org From cell from PBL was obtained by a limiting dilution method using PHA stimulation in the presence of accessory cellsM Thus, progeny of both naive and memory T cells was analyzed and the possibility that selection of precommitted Th precursors play a role in determining the characteristics of the clones generated was excluded. L 1 2 present during the cloning procedures endowed both CD4+ and CD8+ clones with the ability to produce IFN-y at levels severalfold higher than those observed in clones generated in the absence of IL-12. This priming was stable, because the high levels of IFN-y production were maintained when the clones were cultured in the absence of IL-12 for 1 or 2 weeks. The CD4+ and some of the CD8+ clones also produced variable amounts of IL-4. Unlike IFN-y, IL-4 production was not significantly different in clones generated in the presence or absence of IL-12. These data suggest that IL-12 primes the clone progenitors, inducing their differentiation to high IFNy-producing clones. The suppression of IL-4-producing cells observed in polyclonally generated T cells in vivo and in vitro in the presence of L 1 2 was not observed in this clonal model, suggesting that the apparent suppression most likely results from positive selection of non-11-4-producing cells. 84 In the same experimental system, when IL-4 and IL-12 are present during the T-cell cloning, only a minimal inhibitory effect on the IL-12-mediated priming for high IFN-y production was found (Gerosa and Trinchieri, unpublished results).
Human antigen-specific established Th2 clones that were unable to produce IFN-y with any other stimulator did produce IFN-y at low but significant levels when stimulated with IL-12 in combination with specific antigen or insoluble anti-CD3 antibodie~.'~ This induction of IFN-y gene expression was transient, because culture of the established clones with IL-12 for up to 1 week did not convert them into IFNy producers when stimulated in the absence of IL-12. These results suggest that Th clones can respond to IL-12 treatment with either a stable priming for IFN-y production or with only a transient low level expression of the IFN-y gene, depending on the stage of differentiation.
To determine whether IL-12 directly initiates Thl cell development in naive murine T cells, Hsieh et a19 showed that CD4' T cells derived from mice transgenic for an antiovalbumin TCR were induced by ovalbumin to develop into Thl cells in the presence of IL-12, whereas they developed into Th2 cells in the presence of IL-4. The effect of IL-4 was dominant over that of IL-12 when both cytokines were present. Listeria-infected macrophages, by producing IL-12, also induced Thl cell development in CD4+ cells cultured from these mice.' Unlike in the human system, the IL-12-induced development of Thl cells in these TCR transgenic mice was abolished by anti-IFN-y antibodies." The ability of IL-12 to induce development of Th 1 cells and priming for high IFN-y production was confirmed using another strain of TCR (anti-cytochrome C) transgenic mice. Differentiated Thl cells may still require IL-12 for optimal IFN-y production and, at least in part, proliferation. Germann and Rude partially purified a T-cell stimulatory factor (TSF), a soluble mediator involved in the proliferation and IFN-y production of murine Thl cells,",97 which later they proved to be IL-12.x''.98 TSF/IL-12 has proliferative activities, in part through induction of IL-~Rcu, and induces IFN-y production in Thl, but not in Th2 ~l o n e s . ' ' .~~-~~ Furthermore, it was shown that proliferation and IFN-y production by Thl clones in response to antigen and splenic APC was dependent on expression of B7 on APC, synergizing with IL-12.41 Prevention of B7-CD28 interaction with the chimeric recombinant molecules CTLACIg, abrogation of IL-12 activities by specific antibodies, or inhibition of IL-12 secretion For personal use only. on April 14, 2017. by guest www.bloodjournal.org From and B7 expression on APC by 1L-l0 inhibited proliferation and IFN-y production in Thl clone^.^' IL-I has similar costimulatory effects on Th2 clone activity as IL-12 has on Thl clones; Th2 but not Thl clones express 1L-1R.81.1"" However, costimulation by IL-1 has been shown to be required for IL-12-induced IFN-y production by human PBL,"' for the IL-12 priming for IFN-y production in cord blood CD4' cells,"" and for the proliferation and IFN-y production in Thl clones in the presence of macrophage accessory cells, both in antigen-independentgh and -dependent4' experimental systems. However, it is unclear whether in these conditions the effect of IL-l is directly on T cells or, more likely, mediated by the accessory cells. In vivo IP injection of IL-12 in mice resulted in enhanced IFN-y and IL-10 gene expression, reduced basal levels of IL-3 and IL-4 gene expression, and increased serum IgG2a c~ncentration.'"~ The induction by IL-12 of IL-l0 gene expression was unexpected and suggests that L 1 2 in vivo activated the production of a cytokine that profoundly inhibits IL-12 production by a negative feedback mechanism." It remains to be shown whether IL-12, directly or indirectly, induces production of IL-10 from T cells or from other cell types, eg, monocyte/macrophages. In mice that have been injected with goat antimouse IgD antibody, the simultaneous injection of IL-12 suppressed IgG and IgE response, whereas IL-12 had little effect on the IgE response in mice injected with anti-IgE antibodies.IcM When mice were immunized with a hapten-protein conjugate and treated with IL-12, a marked inhibition of IL-4 secreting cells and of antihapten serum IgGl and IgG2b and an enhancement of IgG2a antibodies were observed, whereas little effect on serum IgG3 was noted."" The in vivo effects of IL-12 on Ig isotypes were either not affected'"' or incompletely inhibited" by anti-IFN-y antibodies, indicating that the effect of IL-12 is not uniquely mediated by in vivo induction of IFN-y. Consistent with these observations, the IFN-y-inducing effect of IL-12 in vivo, but not its effects on Ig isotypes, were partially blocked by treatment of the mice with antiasialo GM1 (anti-NK cell) antibodies.'" It is noteworthy that anti-IL-12 antibodies in vivo significantly blocked Thl response to antigen, as evaluated by either IFN-y production or serum IgG2a antibody response.'"' These results strongly suggest that IL-12 has an obligatory role for antigen-induced Thl differentiation in vivo and its effects on Ig isotypes.
Role of IL-12 in Infectious Disease Models in Experimental Animals
The ability of IL-12 to induce acute production of IFN-y and other phagocytic cell activating cytokines (eg, GM-CSF and TNF-a) is particularly important during acute bacterial infection as part of the innate resistance mechanisms. In these defensive mechanisms, NK cells are often responsible for the early production of IFN-y; T cells, although probably also involved, are not essentiaLW The acute production of TNF-a, IL-12, and IFN-y in the endotoxic shock model in mice4" most likely represents an exaggeration of these innate resistance mechanisms, with uncontrolled and often lethal production of these inflammatory cytokines. In chronic infections, IL-12 is responsible for the development of Thl responses that are generally protective for intracellular parasites, but ineffective against other parasites, eg, nematodes. Several experimental models of infectious diseases, reviewed below, are shedding light on these functions of IL-12 in innate and adaptive immune responses to infections.
Listeria rnonocytogenes. IFN-y production by NK cells is necessary in combatting infection in SCID mice, which lack T and B cells, and also in immunocompetent mice.' Heat-killed L. rnonocytogenes in vitro induced splenocytes and macrophages from SCID mice to produce IL-12 and anti-IL-l2 antibodies suppressed IFN-y production by L monocytogenes-treated splenocytes, indicating that IFN-y production in response to Listeria infection is mediated by IL-12." TNF-a, a macrophage factor previously shown to be required for IFN-y production in this experimental system,'"' is now identified as a costimulatory factor for IL-12-mediated induction of IFN-y production in NK cells." Endogenous production of IL-12 is critical for the survival of both immunocompromised SCID mice and normal C.B-17 control mice during a primary infection with a normally sublethal dose of L rnonocytogenes, because anti-IL-12 antibody-treated mice showed a decreased macrophage expression of class I1 MHC antigens and an increased Listeria burden in the spleen and eventually died."' The effect of IL-12 was likely mediated by IFN-y production, because IFN--y treatment of anti-11-12"treated mice limited the spread of the infection and resulted in survival of the SCID mice. l'" Toxoplasma gondii. T gondii is a protozoan parasite normally controlled by a strong and persistent cell-mediated immune response resulting in an asymptomatic chronic infection maintained by dormant tissue cysts. Similar to L monocytogenes, T gondii tachyzoites trigger IFW-y production by NK cells through a pathway that involves the production from macrophage accessory cells of TNF-a and IL-12, cytokines that synergistically trigger the NK cell IFN-y re~ponse.'~ Immunocompetent mice acutely infected with For personal use only. on April 14, 2017. by guest www.bloodjournal.org From sublethal doses of T gondii and treated with either anti-IL-12 or anti-IFN-y were unable to develop an efficient Thl response to the parasite and died within 2 weeks of the infection.'os In contrast, neutralization of endogenously produced IL-12 had no effect when the antibodies are administered during chronic infection.lo8 In agreement with the survival data, treatment with anti-IL-12 resulted in decreased IFN-y and enhanced Th2 cytokine synthesis by splenocytes when administered during acute but not chronic toxoplasmosis.'os However, the production of IFN-y by Thl CD4+ cells was still required for resistance to chronic infection with T gondii because all mice with chronic infection treated with anti-IFN-y antibodies, unlike those treated with anti-IL-12 antibodies, died within 2 weeks."' Overall, these data suggest that the early stimulation of IL-12 plays a major role in both the induction of resistance and Thl cell subset selection in T gondii infection but it is not required for maintenance of established Thl immunity.
Leishmania major. Infection of mice with the protozoan parasite L major is an established in vivo model for the definition of factors that contribute to CD4+ Th cell subset development. Mice that naturally resolve their lesions, such as C3H or CD57BU6, exhibit a dominant Thl response, whereas mice that succumb to the infection, such as BALBI c, exhibit a dominant Th2 response to L major.'0g Treatment of susceptible BALB/c mice with daily doses of IL-12 for at least 1 week starting from the beginning of the L major infection resulted in the survival of most of the mice with a dramatic reduction of lesion size (footpad thickness) and parasite burden and provided durable resistance against reinfection.LLo.L1l Associated with these protective effects, IL-12 treatment induced a decreased production of IL-4 by the draining lymph node cells and increased production of IFNy, suggestive of a shift from a Th2 type of response to a predominantly Thl-type.L'o,"' Delay of IL-12 treatment of 1 week or more resulted in ineffective protection against L major infection, suggesting that, similar to the observation with the Thl response in T gondii infection, it is difficult to change the cytokine production phenotype of an established Th2 response." ' The development of a vaccination protocol for Leishmaniasis infection has encountered many difficulties both in experimental animals and in the clinical practice. A partial protection of BALB/c mice against L major infection was obtained by vaccination with a soluble leishmanial antigen in conjunction with IFN-y and the bacterial adjuvant Corynebacterium parvum."' Vaccination of BALBIc mice with leishmanial antigen and IL-12 promoted the development of leishmanial-specific memory CD4+ Thl these vaccinated mice were completely resistant to subsequent infection with L major. Thus, L-12 is an effective adjuvant for the initiation of protective cell-mediated immunity against leishmaniasis and may be an important component in other vaccines that need to induce cell-mediated immunity. This potential clinical use of IL-12 is particularly promising because only single or a few local injections of limited doses of IL-12 are required for vaccination, likely overcoming possible complications caused by toxicity of the cytokine. It should also be noted that the bacterial adjuvant Cparvum is a powerful inducer of IL-12 production, suggesting the possibility that its adjuvant activity is at least in part mediated by IL-12 production.
The ability of IL-12 to render BALB/c mice resistant to L major infection raises the question whether IL-12 plays a role in the induction of a Thl response in resistant strains of mice. In vitro, L major amastigotes, but not promastigotes, efficiently induced IL-12 production from macrophage~;"~."~ because amastigotes are not present in vivo for several days after natural or experimental infection with metacyclic promastigotes, it was suggested that L major evade IL-12 induction by macrophages in the first few days of infe~tion."~ This hypothesis was supported by the observation that, in BALBlc and C57BW6 mice injected with metacyclic L major, IL-12 p40 mRNA was not measurable in the draining lymph nodes until 7 days after infection.'I4 However, IL-12 p40 protein was released by lymph node cells of C3H and BALB/c mice 1 day after infection with L major, but not in B57BW6 mice.'I5 IL-12 production declined at later times (7 to 14 days) in BALB/c mice, but not in C3H mice.Il5 Neutralizing anti-IL-12 antibodies injected in resistant strains of mice at the time of infection prevented the early (3 days after infection) production of IFN-y and appearance of NK cell cytotoxic activity in the lymph node; the development of a protective Thl response was also prevented and the animals became unable to resist the L major infection."',"' These data suggest that C3H and BALB/c mice, but possibly not C57BU6, produce IL-12 early during infection with L major and that IL-12 production is required for development of a protective Thl response in C3H mice. Because no difference was observed in production of IL-12 or in the ability of NK and T cells of the resistant C3H or susceptible BALBIc to respond to IL-12, the genetic difference in the susceptibility of the two strains to L major is probably not due to IL-12. Preliminary evidence suggests the possibility that factors inhibitory of the IL-12 activity such as IL-4, IL-10, and, particularly, TGF-P could be responsible for the failure of BALB/c mice to develop a Thl response."' TGF-P was indeed shown to inhibit in vitro the generation of a Thl response induced by L-12." Once a Th2 response is established in BALB/c mice, Th2 cytokines such as IL-4 and IL-10 are probably responsible for the downregulation of IL-12 production.
Schistosoma mansoni. Schistosomiasis is a chronic helmintic disease, with morbidity primarily caused by fibrosis mostly resulting from the granulomatous response to parasite eggs in tissues.II6 Unexpectedly, the CD4' T-cell-dependent delayed-type hypersensitivity reaction responsible for granuloma formation is of Th2 type, although a Tho response precedes the Th2 response and both IL-2 and IL-4 are required for granuloma f~rmation."~ Inhibition of IFN-y or IL-12 using neutralizing antibodies in mice infected with S mansoni eggs resulted in a marked enhancement of granuloma formation, concomitant with an increased Th2-and decreased Thl-cytokine mRNA expression.Il8 In contrast, treatment with IL-12 profoundly inhibited granuloma formation and increased Thl cytokine expression, while decreasing Th2 cytokines."' IL-12 could be used also in this experimental system on For personal use only. on April 14, 2017. by guest www.bloodjournal.org From an adjuvant in vaccination. Immunization with S mansoni eggs and IL-12 induced a commitment of their T cells to Thl responses, which allowed only minimal granuloma formation upon subsequent egg challenge."8 These results suggest that the use of IL-12 as adjuvant may allow the development of "antipathology" vaccines1l8 that could prevent schistosoma egg pathology as well as other diseases caused by the production of Th2 cytokines. It is of interest that IL-12 inhibited secondary granuloma formation in mice presensitized with S mansoni eggs."* These latter results indicating that IL-12 can induce a Thl response even in the presence of memory T cells generated during a Th2 biased immune response, confirm previous results in vitro in the human ~y s t e m~,~~ and indicate that the use of IL-12 as a therapeutical agent or an adjuvant in vaccination for inducing a Thl response could be effective even in the presence of Th2-biased memory T cells.
Nippostrongylus brasiliensis.
The immune response to helminths is often characterized by a bias to development of Th2 cells. The question of whether these responses are helpful or harmful has been a controversial issue; the emerging evidence is pointing to the conclusion that Th2 cells and IL-4 play an important role in the control of egg laying and expulsion of the worms.119 N brasiliensis is an intestinal nematode parasite; when infective larvae of the nematode are inoculated orally, they stimulate IL-3, IL-4, IL-5, and IL-9 cytokine production that induces IgE, eosinophil, and mast cell responses. Systemic treatment with daily doses of IL-12 from the beginning of the infection inhibited IL-4, IL-5 , and IL-9 gene expression and induced enhanced expression of IFN-y and IL-10.'2" This effect of IL-12 on cytokine expression during infection was paralleled by a profound inhibition of IgE production and of the intestinal mast cell and eosinophil responses.'2o The inhibition of eosinophil response was sensitive to lower doses of IL-12 than the other responses. Anti-IFN-y antibodies reversed IL-12 inhibition of mast cell and IgE responses, but have little effect on the eosinophil response."' If IL-12 treatment was delayed to 6 days after treatment, it was mostly ineffective, but the eosinophil response was still partially suppressed when the treatment was initiated as late as day 8.12" IL-12 treatment, initiated within the first 6 days of infection, increased egg production and suppressed adult worm expulsion in N brasiliensis-infected mice.'" Thus, IL-12 early treatment can suppress the Th2 response to the nematode and prevent the resolution of the infection; when a Th2 response is established, IL-12, as already shown in other systems, is ineffective in modulating the Th response. Interestingly, the IL-12 treatment during a primary infection partially prevented the development of Th2 responses during a secondary infection, whereas the IL-12 treatment during secondary infection was only partially effective in preventing the development of a Th2 response, possibly because it was antagonized by high endogenous levels of IL-4."" Candida ulbicans. The outcome of systemic challenge of mice with the fungus C albicans is determined by immunologic events occurring shortly after infection; as in the case of L major infection, development of a Thl response is protective, whereas an exacerbative Th2 response is observed in mice challenged with virulent C albicans strain or in the susceptible DBN2 mice challenged with vaccine strain infection."' The expression of IL-12 p40 mRNA was readily detected in macrophages from healing mice, but was detected only early in infection in mice with progressive disease."' Although the mutually exclusive production of IL-WIL-10 and IFN-y by early CD4' T cells is likely to be the major discriminative factor of healing or nonhealing responses in murine candidiasis, IL-12 rather than IFN-./ production appears to be an indicator of early Thl differentiation."' In vivo neutralization of IL-12 with specific antibodies ablated the development of anticandidal resistance and showed the requirement for IL-12 production in resistance to C albicans infection in mice."' However, in mice with progressive systemic disease as well as in a mucosal infection model, administration of IL-12 did not result in therapeutic activity, demonstrating the difficulty in affecting in vivo established or heavily biased Th2 responses."' Virus infections. IL-12 as a potentiator of delayed type of hypersensitivity and of cytotoxic lymphocyte responses should be expected to play a role in the resistance against virus infections. However, surprisingly little information is available on either the importance of endogenous IL-12 or the effect of IL-12 treatment in these infections. Only the effect of repeated daily injections with IL-12 on lymphocyte choriomeningitis virus (LCMV) and murine cytomegalovirus (MCMV) infections in mice has been ana1y~ed.I'~ Surprisingly, IL-12 inhibited rather than enhanced CTL generation during LCMV infecti~n.''~ This inhibitory effect, evident particularly at high doses of IL-12 (20.1 pg daily), was paralleled by an inhibition of the LCMV-induced expansion of CD8' cells.'" This decrease of CD8' cells was not observed in control or in MCMV-infected mice, although in these latter animals a significant decrease of splenic CD4' cells was observed at high IL-12 doses (1 pg daily).Iz4 Although an enhancing effect of IL-12 on the generation of antiviral CTL activity was not observed, a significant reduction in LCMV titer was observed in mice treated with low doses of IL-12 ( 5 10 ng daily), whereas a 2 log increase was observed in mice treated with high doses (1 pg daily).IZ4 The mechanism of these effects have not been investigated, even if the induction of serum IFN-y and TNF-a especially in the LCMV-infected animals treated with high IL-12 doses may explain some of the lymphotoxic effect of IL-l2.IZ4 It is clearly important to extend the analysis of the role of IL-12 to other viruses and to investigate whether virus infection affects IL-12 production and whether IL-12 plays a role in the cell-mediated resistance against virus infections.
IL-12 and HIV
Infection with HIV induces an early deficiency in CD4' Th cell response and, primarily at late stages of the disease, a depression in NK cell cytotoxic activity and in vitro production of IFN-y was reported.lz5""
The depressed NK cytotoxic activity observed in HIVseropositive patients at different stages of the disease is upregulated within a few hours of in vitro treatment with IL-12.@ The cytotoxic activity of IL-12-treated PBL from HIV-infected patients was also efficiently enhanced, not only For personal use only. on April 14, 2017. by guest www.bloodjournal.org From against tumor-derived target cells but also against CMVinfected target cells, to levels similar or slightly higher than those mediated by untreated PBL from healthy donors.64 IL-12 also induces IFN-y production from PBL of AIDS patients, although at lower levels than from cells from healthy controls."*lZ8 Furthermore, addition to IL-12 to PBL from HIV-infected patients in vitro restores in part their defective ability to respond to HIV peptides and to recall antigens or alloantigens.lZ8
The ability of PBMC from HIV-infected patients to produce IL-12 in vitro was evaluated in response to S aureus stim~lation.'~ On average, PBMC from the patients produced approximately 10-fold less IL-12 p40 and fivefold less IL-12 p70 than a panel of healthy donors. Unlike S aureusinduced p40 production, the low constitutive production of p40 detected in unstimulated cultures was not statistically different from controls. In contrast and under the same culture conditions, PBMC from HIV-infected patients produced threefold to fourfold more IL-6 both constitutively and after stimulation than control donors. The production of IL-10, a cytokine able to inhibit IL-12 production, as well as TNFa and IL-IP, was not significantly different in PBMC from HIV-seropositive patients and from control donors. IL-4, a Th-2 cytokine reported to be overproduced in HIV-infected patients, was not detectable in S aureus-stimulated PBMC cultures. These data suggest that the defect in IL-12 production by PBMC of HIV-infected patients is relatively specific and not secondary to a generalized inability of their monocytes to produce cytokines or to overproduction of antagonistic Th-2 cytokines (eg, IL-4 and IL-10).37
Although some studies described a dysregulation of production of cytokines typical of Th-l or Th-2 responses in PBMC or T-cell clones from HIV-infected patients assayed others analyzing cytokine transcript expression.132,'33 Several factors can influence the pattern of cytokines expressed or secreted and therefore might explain these disparate results: anatomic locations and differences in tissue or organ systems and source of APC. In addition, cell type, culture conditions, cloning procedures, cytokine detection assays, and the nature of the stimulus may also play a role in the production of cytokines and proliferation of T-helper cells.
Because d0n0rs.l~~ However, these contrasting findings are not incompatible, because, due to activation by HIV infection or other HIV-associated factors or infections, T cells from patients might constitutively express IFN-y transcripts and secrete IFN-y. At the same time, because of a relative anergy"' associated with the infection and possibly due, at least in part, to lack of priming for high IFN-y production by IL-12, they might be partially unresponsive to stimulation by IFN-y inducers. The decreased ability of T cells from HIV+ patients to proliferate in response to recall antigens or alloantigens could also be compatible with a deficiency in IL-12 production, because IL-12, in addition to being an initiation factor in the immune response, favoring Th-l cell development, is also an important and in some experimental conditions an essential growth factor for differentiated Th-l cells!1*'1*82 Defective IL-12 production is likely to result in inefficient cell-mediated immune responses, although not necessarily in a dominance of Th-2 versus Th-1 cell development. The regulation of Th-l and Th-2 responses in vivo is complex and requires the participation of several other factors in addition to IL-12, none of which probably plays an irreplaceable role. Several factors may render the analysis of the Th-1/Th-2 response in patients difficult. These factors include the possibility that anergy induction in cells with Th-0 or Th-l characteristics, suggested as one of the possible mechanisms of the defective T-cell response in HIV+ patients, might induce in these cells a cytokine profile and other characteristics typical of Th-2 ~e 1 l s . l~~ A deficient production of IL-12 or a defective Thl response may be responsible for the reduced resistance of A I D S patients to opportunistic infections. The requirement for IL-12 production and Thl response in the resistance to Toxoplasma and Candida, two opportunistic pathogens in AIDS, has been reviewed above. Furthermore, it has been shown that IL-12 was produced in the pleural fluid of patients with Mycobacterium tuberculosis-induced tuberculous pleuritis and that anti-IL-12 antibodies partially inhibited the proliferative response of the pleural fluid lymphocytes of the patients in response to M tuberculosis. These results indicate the possible importance of IL-12 production in the immune response to another opportunistic pathogen important in AIDS patients.
IL-12 and Antitumor Immunity
The ability of IL-12 to facilitate cell-mediated immune responses, including enhancement of NK cytotoxicity, generation of CTL, and macrophage activation, suggests that it could have a role in both the innate and adaptive resistance mechanisms against tumors. In vitro, IL-12 was shown to enhance the cytotoxicity mediated by NK cells from healthy donors against colon carcinoma and neuroblastoma cell hairy cell leukemia patients,'43 and to stimulate proliferation and cytotoxicity against autologous tumor cells mediated by lymphocytes infiltrating different types of tumors.144.'45 Studies using transplantable tumors in experimental animals have shown a dramatic effect of IL-12 in decreasing tumor growth and metastasis formation and in significantly delaying death.'34 Systemic daily treatment (5 days per week) had a significant inhibitory effect on the growth of metastasis lines,141.142 to enhance cytotoxicity of NK cells from most For personal use only. on April 14, 2017. by guest www.bloodjournal.org From induced by intravenous injection of B 16 melanoma cells and efficiently inhibited the growth of subcutaneously injected tumors, even when treatment was initiated 2 weeks after tumor inoculation.i34 An inhibitory effect of IL-12 on tumor growth, with a greater than twofold increase in survival of inoculated animals, was also observed with the reticulum cell sarcoma M5076 and with the renal cell adenocarcinoma Renca. i34 In this latter tumor, complete remission, especially with peritumoral injection of IL-12, was observed in some animals; reinjection of the Renca cells in the "cured" animals resulted in delayed growth of the tumor, suggesting that L 1 2 may induce a memory immune response against the tumor."4 The antitumor effect of IL-12 is mostly independent of NK cells, but requires CD8' cells for an optimal response." 4 The effect of paracrine secretion of L 1 2 was examined using the poorly immunogenic BL-6 murine melanoma cell line admixed with allogeneic fibroblasts transfected with cDNAs encoding both chains of IL-12 and secreting biologically active IL-12 h e t e r~d i m e r . '~~ The emergence of detectable tumors was significantly delayed in mice receiving injections of BL-6 admixed with transfected fibroblasts, but not in those receiving BL-6 admixed with control fibroblasts not producing IL-12; the delay was proportional to the amount of produced IL-12.'34 Immunization with irradiated tumor cells admixed with fibroblasts producing low levels of IL-12 followed by a subsequent tumor challenge resulted in delay of tumor appearance, indicating the possibility of using IL-12 in the preparation of cancer vaccines.'46 The tumors growing after injection of tumor cells admixed with IL-12-producing fibroblasts were characterized by an extremely reduced lymphocyte infiltrate and by a characteristic fibroblastic capsule around the tumor.'46 The C26 murine colon carcinoma induces tumors that are minimally sensitive to in vivo systemic treatment with IL-12; transduction into C26 cells of both IL-12 genes using a polycistronic retroviral vector resulted in cells that produced low levels of L 1 2 and that were significantly delayed in inducing tumor formation in vivo.'47 The delayed growth of the IL-12-producing C26 cells was due to NK cells and, in part, to CD8' ~e1ls.l~' The in vivo growing tumors was characterized by an extremely poor lymphocytic infiltrate; however, in vivo depletion of CD4' cells resulted in a significant increase in tumor infiltration with CD8' and NK cells and in complete remission of the tumor in approximately half of the animals.'47
These results suggest that, as observed in other experimental tumor system^,'^'.'^^ the IL-12-transduced C26 cells may activate CD4' cells that have an inhibitory activity on the tumor infiltration and antitumor activity of CD8' cells; the complexity of the cellular mechanisms involved in tumor immunity cautions against premature generalizations of the results obtained in few experimental models for the planning of possible therapeutic manipulation in cancer patients.
CONCLUSION
In the short time since its first description in 1989,' IL-12 has been emerging as a central cytokine in immune response, with the potential of therapeutic application in a variety of disease states. Being produced by phagocytic cells and other antigen-presenting cell types and involving in many aspects of its immunomodulating functions the participation of NK cells, IL-12 represents a bridge between innate resistance and adaptive immune response. IL-12 is produced early during the response to infectious agents or to other antigens and induces production of IFN-y first primarily by NK cells and then by T cells. This early response is important for the activation of the phagocytic cell system as a first line of defense against infections, but the IL-12 produced in this early phase, often acting in combination with the induced IFN-y, is also required for optimal generation of Th 1 CD4' cells and CTL. The present evidence suggests that the bias of the immune system to either Thl or Th2 response is regulated by the balance of IL-12 and IL-4 early during the immune response. IL-12 is therefore a true initiation cytokine for cell-mediated responses"" and its production is a requirement for early activation of the phagocytic cell system and generation of Thl responses. IL-12 is also a costimulatory factor for differentiated Thl cells and required for optimal proliferation and IFN-y production by Thl cells in response to antigens. However, an established Thl response is stable and IL-12 does not appear to be an absolute requirement for its maintenance. The central role of IL-12 in the biology of immune response suggests the possibilities of its therapeutic use in infectious diseases, allergic diseases, tumors, immunodeficiencies, and as an adjuvant in vaccination; conversely, the antagonists of IL-l2 action might have indications in certain autoimmune diseases or parasitic infections. Because of the biologic and possibly clinical relevance of this cytokine, it is important that its biologic functions continue to be investigated and, in particular, that the molecular mechanisms leading to its production are elucidated. 
